• John H Rex, Barry I Eisenstein, Jeff Alder, Mark Goldberger, Robert Meyer, Aaron Dane, Ian Friedland, Charles Knirsch, Wendy R Sanhai, John Tomayko, Cindy Lancaster, and Jennifer Jackson.
• University of Texas Medical School at Houston, Houston, TX, USA. john.rex@astrazeneca.com
• Lancet Infect Dis. 2013 Mar 1;13(3):269-75.

AbstractTo bring new antibacterial drugs to the market is challenging because discovery of new agents is difficult, two large trials per indication are needed in accordance with traditional regulatory requirements, and the economic reward is limited if the use of new antibiotics is constrained. These challenges have resulted in an alarmingly thin antibiotic pipeline, despite the rapid and continued growth in the need for new drugs. Approaches that balance the quantity of data needed for registration with the unmet medical need would encourage work in this area. Therefore, a tiered regulatory framework that allows either disease-based or pathogen-based label indications is proposed, with label wording that promotes the most appropriate use of new agents. Such a framework is within the bounds of present regulatory approaches, is amenable to international harmonisation, and would be a welcome step towards the facilitation of a robust and sustainable discovery and development infrastructure.Copyright © 2013 Elsevier Ltd. All rights reserved.

11 keywords...

hide…